Protocol

Intermittent hypoxic-hyperoxic training (IHHT)

IHHT · Intermittent hypoxia hyperoxia therapy · ReOxy · Intermittent hypoxic-hyperoxic therapy · Altitude training at sea level · Hypoxic training · Interval hypoxic training

There is genuine human controlled data, but not for longevity. The strongest available study (Bahenský et al. context aside, the key trial is the German long COVID study, PMC11634465) was a prospective, controlled, OPEN-TREATMENT, NON-RANDOMISED pilot in 145 inpatients at a single German rehabilitation centre. The IHHT arm (n=70) improved 6-minute walk distance 2.8-fold more than standard care (91.7 m vs 32.6 m, p<0.001), with secondary gains in stair-climbing power, dyspnoea, fatigue, quality of life and handgrip. The authors themselves state the design had limited strength due to absence of blinding and non-random assignment, producing baseline imbalance between groups. So: this is deconditioned post-viral patients regaining function during a five-week inpatient rehab programme, not healthy adults gaining healthspan. What the evidence does NOT show: any effect on mortality, biological age, epigenetic clocks, or any longevity or healthspan endpoint; any benefit in healthy or asymptomatic people; any durability beyond the treatment window. The mitochondrial-rejuvenation and anti-ageing claims made in clinic marketing are mechanistic extrapolation, not demonstrated outcomes. Safety signals appear benign in supervised use, though the "no reported adverse events" claim cited by at least one Australian provider rests on an unpublished 2015 literature review, which is not verifiable evidence. Note also that provision in Australia sits mainly with naturopathic and wellness practices rather than medical longevity clinics, which is itself informative about how the intervention is positioned.

At a glance

Evidence
Commercial
Singapore (HSA)
No HSA position on file
Australia (TGA)
NOT INDEPENDENTLY VERIFIED - treat as a distributor claim, not as established fact. The Australian ReOxy distributor states on its own site, verbatim: "ReOxy device is entered in the Australian Register of Therapeutic Goods (ARTG 408421)". I was unable to confirm this against the TGA's own register: tga.gov.au/resources/artg/408421 timed out on repeated attempts and the ARTG search interface was unreachable in this session, so the sponsor, device class and, critically, the registered intended purpose remain unconfirmed. An ARTG entry, if it exists, would establish only that the device may lawfully be supplied in Australia for its registered intended purpose; it would NOT constitute TGA endorsement of anti-ageing, longevity or healthspan claims. Separately, none of the Australian provider pages reviewed (Tsavo Wellness, The Orchard, Rosalba Courtney) make any TGA or ARTG claim at all, and The Orchard positions ReOxy explicitly as a wellness service rather than a medical treatment. BEFORE PUBLICATION: the ARTG number 408421 must be checked directly against the TGA register and the registered intended purpose quoted.
Offered at
No clinic on file

Singapore

Health Sciences Authority

HSA status
No position on file
In our SG set
Not tracked in Singapore
SG clinics
None on file

Australia

Therapeutic Goods Administration

TGA status
NOT INDEPENDENTLY VERIFIED - treat as a distributor claim, not as established fact. The Australian ReOxy distributor states on its own site, verbatim: "ReOxy device is entered in the Australian Register of Therapeutic Goods (ARTG 408421)". I was unable to confirm this against the TGA's own register: tga.gov.au/resources/artg/408421 timed out on repeated attempts and the ARTG search interface was unreachable in this session, so the sponsor, device class and, critically, the registered intended purpose remain unconfirmed. An ARTG entry, if it exists, would establish only that the device may lawfully be supplied in Australia for its registered intended purpose; it would NOT constitute TGA endorsement of anti-ageing, longevity or healthspan claims. Separately, none of the Australian provider pages reviewed (Tsavo Wellness, The Orchard, Rosalba Courtney) make any TGA or ARTG claim at all, and The Orchard positions ReOxy explicitly as a wellness service rather than a medical treatment. BEFORE PUBLICATION: the ARTG number 408421 must be checked directly against the TGA register and the registered intended purpose quoted.
In our AU set
Tracked in Australia
AU clinics
None on file
Evidence is not approvalAn evidence grade describes how strong the science is. A regulatory status describes whether a body has approved the intervention for an indication. They are different questions, answered separately above.

What it is

Plain-language explainer

IHHT is a breathing protocol in which a person alternates, through a mask, between inhaling low-oxygen air (roughly 10 to 12 percent O2, simulating altitude) and oxygen-enriched air (roughly 30 to 35 percent O2), in cycles over a 30 to 60 minute passive session. In Australia it is delivered almost entirely via the ReOxy device, developed in Luxembourg and manufactured in Germany, which adjusts the hypoxic dose to the individual's measured response. Providers claim it improves mitochondrial function, cellular energy metabolism, endurance, stress resilience, sleep, cognition and fat metabolism; the longevity framing is built on the mitochondrial and hormesis story rather than on longevity outcome data.

Categories

Protocol

Keep reading

Related coverage from the newsroom.

Suggest an updateJoin the community

Every entity profile on variis is sourced. Not medical advice.